Non-opioid focus Target opportunities in the non-opioid pain therapeutics space, highlighting Concentric Analgesics’ lead candidate vocacapsaicin for postsurgical pain to align with hospitals seeking opioid-sparing options.

Clinical-stage partnerships Leverage their clinical-stage status and existing collaborations (e.g., URMC) to propose co-development, research collaborations, or sponsored clinical studies with academic centers and contract research organizations.

Poster data momentum Capitalize on recent and past conference presentations to drive discussions with key opinion leaders and hospital systems about adoption timelines and payer discussions for vocacapsaicin.

Financial runway Position as a partner for late-stage development or strategic investments given over 100 million in funding history and ongoing clinical-program advancement, appealing to investors and pharma looking for early-stage collaboration.

Surgeon and pain market fit Target orthopedic, hip and knee surgeons, and regional anesthesiology departments with pain-management solutions that reduce opioid use, aligning with their ASRA/AAHKS data presentations and surgical recovery workflows.